Terms of the deal were not disclosed.
Jordi Labs provides chemical characterization, complex product deformulation and contaminant and failure investigations for medtech manufacturers.
“As the only medtech service provider rooted in almost 40 years of regulatory strategy, RQM+ is proud to now offer proprietary testing services for extractables and leachables, which gives our customers the fastest path to regulatory approvals,” RQM+ CEO Margaret Keegan said in a news release. “We are relentlessly focused on being the best at every service we provide to medtech manufacturers. Jordi’s world-leading testing services will help us maintain our uncompromising quality standards at every stage as we grow into a one-stop-shop to expedite patient access to life-improving technologies.”
Formerly known as Regulatory and Quality Solutions, Monroeville, Pennsylvania-based RQM+ has been a portfolio company of Chicago-based private equity firm Linden Capital Partners since August 2021. RQM+ called itself the largest medical device- and diagnostics-focused regulatory and quality consulting company in the world following its 2020 acquisition of Maetrics.
“We are delighted to now be a part of the RQM+ solution that brings customers to market faster with our unmatched track record of rapid testing results that satisfy the stringent requirements of regulators globally,” Jordi Labs President Mark Jordi said in the news release. “Joining RQM+ will enable me to focus on what I love – developing groundbreaking technology that ensures patient safety by setting new standards for extractables and leachables testing.”
In March, RQM+ named Keegan as CEO to replace co-founder Maria Fagan, who retired as CEO but joined the board as vice chair. Keegan was previously chief operating officer of PRA Health Sciences (now ICON) and served as president of clinical development for IQVIA before that.